PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Contraception, Postcoital”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1991

Postcoital contraception.

Explore the source record for details and available documents.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed2000

Use of 0.75 mg Levonorgestrel for postcoital contraception in Thailand.

OBJECTIVE: This study identified the pattern of Levonorgestrel (LNG) use and self-reported side-effects among Thai women in Songkla. METHOD: The eligible subjects were 100 Thai women who had used 0.75 mg LNG at least once in the past 12 months. The participants completed a questionnaire at the survey sites, which were seven pharmacies and five shopping malls. RESULTS: Eight percent of LNG users had never used any contraceptive methods other than day count and withdrawal. Thirty-nine percent took more than four tablets of LNG per month, which was the limit instructed in the label. Only 3% used LNG for emergency situations such as having unprotected intercourse or burst condom. At least 22% of subjects took LNG according to instructions which were last revised 2 years earlier. The study also revealed poor knowledge among the users on side-effects and limit of drug use. Compared to the previous studies, this study found a higher incidence of side-effects. Forty-four percent of subjects experienced cycle disturbances and 32% nausea, respectively. CONCLUSION: The Thai FDA should seriously consider requiring manufacturers to revise labels of LNG to be consistent with those recommended by WHO.

Adult↗
PubMed1984

The effect of a single midcycle administration of 0.5 or 2.0 mg dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one) on pituitary and ovarian function--investigation for the use as a postcoital contraceptive.

Estradiol-17 beta, progesterone, LH and FSH levels in plasma were measured simultaneously by radioimmunoassay and BBT was recorded in order to investigate the effect of a single midcycle oral dose of 0.5 or 2.0 mg dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-estra-4,9-dien-3-one, VEB Jenapharm, Jena/GDR) on pituitary and ovarian function in 18 healthy fertile females. After application of 0.5 mg dienogest in the follicular phase the cycles appeared to be anovulatory. Administration of 2.0 mg two days prior to the expected LH-surge produced a delay of the LH-peak combined with an absence of ovulation as well as the absence of the normal subsequent increase of progesterone. With 0.5 mg the delay of the LH-surge was followed by an ovulation with normal corpus luteum function. The application of 0.5 or 2.0 mg one day before or during the rising LH-peak lowered the LH-surge but ovulation and luteal phase were not altered. Administration of both dosages during the LH-peak could neither prevent ovulation nor disturb corpus luteum function. Postovulatory ingestion of 0.5 or 2.0 mg dienogest during the BBT-rise produced no alteration of the further cycle. These results demonstrate that dienogest in a single-dose-administration in midcycle can alter pituitary and ovarian function depending on the time interval between application and the day of LH-surge.

Adult↗
PubMed2001

Mifepristone: a potential postcoital contraceptive.

Mifepristone is an orally-active progesterone receptor antagonist. When a single dose of mifepristone is given in the mid- or late follicular phase, it may diminish or inhibit the luteinising hormone (LH) surge. In the early luteal phase, a single dose of mifepristone induces significant changes in the endometrium without affecting the hormonal levels or menstruation. When it is given in the mid-luteal phase, there will also be significant changes in the endometrium and some women may have two episodes of vaginal bleeding. A clinical trial suggests that a single dose of mifepristone in the early luteal phase may be an effective contraceptive agent but the lack of a cheap and easy method to identify the LH surge limits its clinical application. The administration of mifepristone alone or in combination with a prostaglandin does not appear to be an effective form of contraception. When used together with a prostaglandin, it may be an effective method for menstrual regulation but the cost and possible side effects of the prostaglandins limit its use. Mifepristone is a very effective method for emergency contraception. The incidence of side effects was also lower than that of the Yuzpe regimen. Lowering the dose of mifepristone from 600 to 10 mg does not decrease its efficacy but the incidence of delay in onset of the subsequent menses is reduced. Despite its efficacy, the reputation of mifepristone as an abortion pill may limit its access in many countries.

Contraception↗